NCT07120282 2026-03-09Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLCCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Recruiting108 enrolled
NCT06877299 2026-01-02Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage â…¡A-â…¢B Non-small Cell Lung CancerSichuan UniversityPhase 2 Recruiting30 enrolled